TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biofrontera ( (BFRI) ) just unveiled an update.
On September 16, 2025, Biofrontera Inc. held a Special Meeting of Stockholders where several key proposals were approved. These included an amendment to the company’s certificate of incorporation to potentially conduct a reverse stock split to comply with Nasdaq listing requirements, and the issuance of common stock related to Series C and D Preferred Stock conversions. These decisions are aimed at strengthening Biofrontera’s market position and ensuring compliance with stock exchange regulations.
The most recent analyst rating on (BFRI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall score is primarily driven by its financial challenges, including negative profitability and cash flow issues. The earnings call provided some optimism with record sales and strategic changes, but valuation concerns and neutral technical indicators weigh down the score.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. operates in the pharmaceutical industry, focusing on dermatology products and treatments. The company is known for its innovative solutions in skin health and is actively engaged in maintaining its market presence through strategic decisions.
Average Trading Volume: 217,572
Technical Sentiment Signal: Hold
Current Market Cap: $9.07M
See more insights into BFRI stock on TipRanks’ Stock Analysis page.